BIAF bioAffinity Technologies, Inc.

NEUTRAL Impact: 3/10 S-1/A
Horizon weeks Filed Jun 16, 2026 Processed 4d 12h ago SEC 0001493152-26-028877
IPO registration amendment
Latest settled — T+1d ⚠ clustered
BIAF ▲ +0.65% at T+1d
NEUTRAL call ✓ call won +0.65% · α vs SPY -0.13% · entry $0.8318 → $0.8372
Next anchor: T+5d in 3d
Last close $0.8370 (close Jun 18) · +0.63% from $0.8318 entry
Entry anchored
Jun 16, 03:58 PM ET
via Databento tick
T+1d
+0.65%
call +0.65% · α -0.13%
$0.8372
settled 4d ago
T+5d
call — · α —
in 3d
T+20d
call — · α —
in 24d
T+60d
call — · α —
in 3mo

Executive Summary

bioAffinity Technologies filed Amendment No. 1 to its S-1 registration statement, a procedural update adding the Placement Agency Agreement and forms of Pre-Funded and Placement Agent Warrants. The offering terms remain undisclosed, and the company's going-concern warning and declining revenue persist from the prior filing. This amendment does not alter the material terms or financial outlook.

Actionable Insight

Monitor for pricing and closing of the offering; the company's cash runway is critical given the going-concern warning. The procedural filing does not change the bearish fundamental outlook from the prior S-1.

Key Facts

  • Amendment No. 1 to S-1 filed June 16, 2026, adding Exhibit 1.1 (Placement Agency Agreement) and Exhibits 4.44/4.45 (warrant forms).
  • Placement agent WallachBeth Capital receives 7.5% cash fee, up to $120,000 expense reimbursement, and warrants equal to 3% of shares sold.
  • Offering size and pricing remain undisclosed (placeholders $[*] in the agreement).
  • Company has a going-concern warning, $3.1M cash (as of March 31, 2026 per prior filing), and accumulated deficit of $72.2M.

Financial Impact

Undisclosed offering size; prior S-1 targeted ~$3.4M net proceeds. This amendment does not change the financial terms.

dilutioncash position

Risk Factors

  • Going-concern risk with limited cash and accumulated losses.
  • Significant dilution from the offering and outstanding warrants/preferred stock.
  • Revenue decline of 36% YoY in Q1 2026 (per prior filing).

Market Snapshot

Exchange
Nasdaq
Sector
Services-Commercial Physical & Biological Research
Analyst Consensus
0% bullish (6 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
S-1/A Filing (Primary)0001493152-26-028877
Exhibit: ex4-45.htm0001493152-26-028877
Exhibit: ex1-1.htm0001493152-26-028877
7 reports for BIAF
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for BIAF — sortable, filterable
Type Now
Jun 18, 2026
2d ago
424B4
BEARISH ★ 7/10
$0.8569 awaiting T+1awaiting T+1$0.8370 (+2.32%)
Jun 17, 2026
4d ago
EFFECT
BEARISH ★ 7/10
$0.8318 $0.8372▼ −0.65%▲ +0.13%$0.8370 (−0.63%)
Jun 16, 2026
4d ago
S-1/A
NEUTRAL ★ 3/10
$0.8318 $0.8372▲ +0.65%▼ −0.13%$0.8370 (+0.63%)
Jun 16, 2026
4d ago
8-K
NEUTRAL ★ 2/10
$0.9448 $0.8318▼ −11.96%▼ −10.71%$0.8370 (−11.41%)
Jun 12, 2026
8d ago
S-1
BEARISH ★ 6/10
$1.37 $0.9448▲ +31.04%▲ +30.44%$0.8370 (+38.91%)
Mar 3, 2026
15w ago
8-K
NEUTRAL ★ 3/10
$1.03 $1.03· 0.00%▲ +0.57%$0.8370 (−18.74%)
Feb 25, 2026
16w ago
8-K
NEUTRAL ★ 4/10
$1.09 $1.04▼ −4.59%▼ −4.04%$0.8370 (−23.21%)
Showing 7 of 7

US Market Status

Market Closed — Opens Mon (28h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access